PDF(Pubmed)
Abstract：
Cytotoxic T lymphocytes (CTLs), also known as CD8+ T cells, participate in immune function by secreting various cytokines after recognizing specific antigens and class I major histocompatibility complex molecules associated with tumor cells, and thus have a key role in antitumor immunity. However, certain CD8+ T cells show low reactivity and thus cannot effectively remove tumor cells or viral antigens. Due to this heterogeneity, effective biomarkers representing these differences in CD8+ cells are needed. The identification of suitable biomarkers will also enhance the management of cancer treatment. Recent research has improved the understanding of CD8+ T lymphocytes in the tumor microenvironment and circulatory system. Treatment efficacy is impacted directly by the pathogenic response of CTLs, and thus, the use of adjuvant therapies to address these pathological changes, e.g., stimulating the increase in the proportion of reactive T cells or suppressing the proportion of terminally exhausted T cells, would be advantageous.
摘要：
细胞毒性T淋巴细胞（CTL），也被称为CD8+T细胞，通过识别与肿瘤细胞相关的特异性抗原和I类主要组织相容性复合物分子后分泌各种细胞因子参与免疫功能,因此在抗肿瘤免疫中起关键作用。然而,某些CD8+T细胞显示低反应性,因此不能有效去除肿瘤细胞或病毒抗原。由于这种异质性，需要代表CD8+细胞中这些差异的有效生物标志物。合适的生物标志物的鉴定也将增强癌症治疗的管理。最近的研究提高了对肿瘤微环境和循环系统中CD8T淋巴细胞的认识。治疗效果直接受到CTL的致病反应的影响，因此，使用辅助疗法来解决这些病理变化，例如，刺激反应性T细胞比例的增加或抑制终末耗尽T细胞的比例，将是有利的。
